Dr Reddy's share price today

Dr Reddys Laboratories Ltd's share price was ₹1,374.00 at the close on 4 November 2026. It has been falling for 13 weeks. That is 11.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,148 and ₹1,374, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Dr Reddys Laboratories Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 5 weeks in a row.

Over the last 11 years the share price moved +111% while the NIFTY 500 moved +249%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) cut their stake for 10 quarters in a row, indian funds and insurers (DIIs) raised their stake for 10 quarters in a row and profit down on a year earlier for 5 quarters in a row.

1. Foreign funds (FIIs) cut their stake for 10 quarters in a row

   From 29.1% to 20.3% of the company by the September 2026 quarter.

2. Indian funds and insurers (DIIs) raised their stake for 10 quarters in a row

   From 18.3% to 31.9% of the company by the September 2026 quarter.

3. Profit down on a year earlier for 5 quarters in a row

   In the September 2026 quarter profit was ₹913 crore, -31.7% on a year earlier.

   Why: Profit fell mainly because sales of Lenalidomide, a large North American generic medicine, kept shrinking.

   Next results: check whether new product launches and the rest of the North American business keep growing enough to make up for falling Lenalidomide sales.

   From the earnings call on 23 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Dr Reddy's reported revenue of ₹8,698 crore, down 1.5% from ₹8,828 crore a year earlier, and a profit of ₹913 crore, down 31.7% from ₹1,337 crore.

Dr Reddy's results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Dr Reddy's' management discussed these results on a call held on 23 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Dr Reddy's closed at ₹1,374.00 on 4 November 2026, up 14.0% from ₹1,205.40 a year earlier (7 November 2025) and up 44.1% over five years. Its highest weekly close since March 2016 was ₹1,406.27 on 30 August 2024.

Dr Reddy's share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 4 March 2016 to 4 November 2026.

4 Nov 2026: Dr Reddy's closed at ₹1,374.00, up 1.6% on the week and up 13.9% on the month. 23 Oct 2026: Dr Reddy's held its results call for July to September 2026. Management guided: Semaglutide relaunch in November 2026 after validation; FY27 delivery 6-7 million pens, tentative 12-15 million run-rate estimate and 89-market goal.

Earlier

• Results for July to September 2026: Revenue down 1.5% and profit down 31.7% on a year earlier.
• 10 Jul 2026: ex-date for a dividend of ₹8 a share.
• 28 Oct 2024: Share split: face value cut from ₹5 to ₹1 a share (ex-date).

Dr Reddy's paid ₹8 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.58% at the ₹1,374.00 close on 4 November 2026. The last was a dividend of ₹8 a share, ex-date 10 July 2026.

Dr Reddy's dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Dr Reddys Laboratories Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 23 October 2026, Dr Reddy's' management guided: Semaglutide relaunch in November 2026 after validation; FY27 delivery 6-7 million pens, tentative 12-15 million run-rate estimate and 89-market goal.

“Subject to successful validation, we expect to relaunch Semaglutide directly as well as through our partners in November 2026, consistent with the timelines communicated earlier.”Erez Israeli, on the call for July to September 2026

What management guided

• Gross margin 50-55%; operating profit 20%+ sustainable, aiming for 25% and 21%+ with successful semaglutide.
• SG&A around 32% for the rest of FY27; R&D 7-8% in coming quarters; war-related KSM, solvent and freight drag around 100 basis points of operating profit through Q3-Q4.
• SC filing around February-March 2027, US SC January to March 2028 and non-US IV/SC April to June 2027; potential hundreds of millions of dollars.
• FY27 capital spending ₹1,600-1,700 crore.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 23 October 2026.

When Dr Reddy's reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Semaglutide drug-product validation and partner supply; check relaunch timing and availability in the stated launch markets.

Dr Reddy's is on 5 of our India lists: Momentum stocks, Breakout stocks, Nifty 50 companies, 52 week high & low and Pharma stocks.

Dr Reddys Laboratories Ltd earned ₹913 Cr of net profit in the Sep 2026 quarter, −31.7% on the same quarter a year earlier. Full-year FY26 profit was ₹4,158 Cr. Over 10 years profit has grown 6.9% a year on average. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned ₹1,337 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹4,158 Cr (−27.4% on the year before).

Why profit moved: revenue changed −1.5% on a year earlier and the margin moved −3.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −50.5% and revenue −3.5%. Profit is growing slower than sales: rising costs are taking part of the growth.

Dr Reddys Laboratories Ltd reported ₹8,698 Cr of revenue in the Sep 2026 quarter, −1.5% on the same quarter a year earlier. Over 10 years it has grown 8.0% a year on average. The last full year, FY26, came in at ₹33,700 Cr. The last four reported quarters add to ₹33,097 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. Semaglutide is the single most important new revenue driver for the next 3 years. Health Canada approval for injectable semaglutide gives Dr Reddy's first-mover advantage in a market where the originator (Novo Nordisk) commands premium pricing. India launched as Obeda on November 2025 patent expiry. The near-term geometry: 6 to 7 million units by end CY26 (across approved + about-to-approve markets), ramping to 12M in FY27, with potential 40M+ per year upon FTO-11 qualification in FY28. Pricing: list price ~50% of Novo, net realization $25 to 30/unit in most markets (higher in premium geographies). Brazil remains a near-term risk (ANVISA review, 3 to 4 month delay confirmed) but management retains…

FY26 revenue was ₹33,700 Cr, +3.2% on the year before.

Recent pace: the last four quarters grew −3.5% on average, against 8.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −3.5%, against +4.9% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −51.9%, against −28.7% a year (rolling over).

Dr Reddys Laboratories Ltd's operating margin was 20.0% in the Sep 2026 quarter, 3.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 14.0% and 28.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −3.0 percentage points on the year while gross margin changed −1.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 96% of Dr Reddys Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹5,674 Cr of operating cash against ₹4,158 Cr of profit. After ₹4,890 Cr of spending on assets, ₹784 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 96% of profit came in as cash: the cash cycle got 12 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 3.5× depreciation over three years. The next section checks what that spending is building.

Dr Reddys Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 247 days in FY26, down from 259 days in FY21. It spent ₹18,507 Cr on assets over the last 3 years. Customers take 110 days to pay, and stock sits for 228 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹33,700 Cr, each day of that cycle ties up about ₹92.3 Cr, so roughly ₹22,805 Cr is tied up in the business at any time.

FY26: customers took 110 days to pay and stock sat for 228 days, about 7.5 months of sales sitting as stock, for a full cycle of 247 days, shorter than FY21's 259.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 228 days. Customers pay about 110 days after that. Suppliers are paid at 91 days. Together that makes the 247-day cycle.

Spending on assets: ₹18,507 Cr over the last 3 years, against ₹5,233 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹1,460 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Dr Reddys Laboratories Ltd's P/E is 41.0×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 26.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.